Passage prices upsized IPO despite market headwinds

The ability of Passage Bio to price its IPO above expectations late Thursday signaled that even with a global pandemic roiling markets, a new biotech listing can still pique investors’ interest.

Gene therapy company Passage Bio Inc. (NASDAQ:PASG)

Read the full 375 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE